

D-HF 2021 Program

Friday, December 10

Time	Title	Speaker	Min
07:00 – 08:00	Welcome and breakfast		60
8:00-10:00	Neuromodulation in the management heart failure and its comorbidities: diabetes, sleep apnea and hypertension		120
	Moderators: Felix Mahfoud, Howard Levin, Kalyanam Shivkumar,		
	Panelists:,,, Kerstin Piayda		
	Q&A moderator:		
	Translational concepts in the development of new treatment strategies	Kalyanam Shivkumar	8
	Renal denervation for heart failure treatment:		
	Renal denervation for HFpEF: trial design considerations - how can RDN learn from trials of inter-atrial shunt trials and SGLT-2 inhibitors	Philipp Lurz	8
	Renal denervation for HFrEF: how to design trials given all the other treatments available - where would RDN fit in this crowded space?	Felix Mahfoud	8
	<i>Discussion</i>		
	Treatment of central sleep apnea in heart failure patients: Remede	Marat Fudim	8
	Update on electrical barostimulation	TBC	8
	Stent-based barostimulation: Results of the first in man trial	Horst Sievert	8
	An endovascular approach for treating HF patients using an implantable active Neuromodulation Implant	Jozef Bartunek	8

	Metavention: Renal and hepatic artery denervation to treat metabolic syndrome	Horst Sievert	8
	Vagus nerve stimulation	<i>Gaetano De Ferrari</i>	8
	Atrial fibrillation in heart failure	Christian Ukena	8
	<i>Discussion</i>		...
10:00 - 10:30	Coffee break		30
10:30-11:20	Pathogenesis and treatment of heart failure with preserved ejection fraction (HFpEF)		50
	Moderators:,		
	Panelists:,,,		
	Q&A moderator:		
	What are the underlying causes of HFpEF	<i>Thibaud Damy</i>	8
	<i>Discussion</i>		5
	The many faces of HFpEF – not just one disease	...	8
	<i>Discussion</i>		5
	The failures, the learnings and the encouraging future - overview of potential therapies for HFpEF (medical therapy, clinical trial design, devices)	<i>Scott Solomon</i>	8
	<i>Discussion</i>		4
	What is the causal role for Tricuspid Regurgitation in HFpEF?	Yan Topilsky	8
	<i>Discussion</i>		4
11:20-12:35	The splanchnic bed is a novel target in patients with heart failure with preserved ejection fraction (HFpEF)		75
	Moderators: Howard Levin,		
	Panelists:,,,		

	Q&A moderator:		
	Overview of the physiology of the splanchnic bed in HFpEF and HFrEF	Marat Fudim	10
	Long-term follow-up on FIH endovascular therapy using the Satera Ablation System in HFpEF and HFrEF	<i>Sanjiv Shah</i>	10
	Where does this therapy potentially fit into current landscape of treatments for HFpEF and HFrEF	Piotr Ponikowski	10
	Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF	<i>Sanjiv Shah</i>	10
	Proposed design of the worldwide Pivotal Clinical HF trial	Howard Levin	10
	<i>Discussion</i>		25
12:35-12:50	Pick up your lunchbox		15
12:50-14:00	Telemedicine		70
	Moderators: William Abraham , Stefan Anker		
	Panelists:,,,		
	Q&A moderator:		
	Telemedicine advancements during the COVID-19 pandemic: What's worked, what hasn't, and what's to come?	Rob Califf	7
	Non-invasive assessment of lung fluid content	TBC	7
	Implantable Hemodynamic Monitors		
	CardioMEMS...	Philip Adamson	7
	The first in heart microcomputer for the management of HF patients	William Abraham	7
	Exercise stress testing in remote heart failure management	Jozef Bartunek	...7
	<i>Discussion</i>		

	Non-invasive assessment of fluid status and arrhythmogenic	David Kuraguntla	7
	Payer perspective	Joe Chen	7
	<i>Discussion</i>		21
14:00-15:00	Durable mechanical circulatory support		60
	Moderators: Navin Kapur, Daniel Burkhoff		
	Panelists: Bhavsar, ..., ..., ...		
	Q&A moderator: ...		
	Durable MCS state of the art	Bart Meyns	7
	CorWave LVAD - a biomimetic ump for physiologic pulsatility	Trevor Snyder	5
	HeartMate 3	TBC	5
	Carmat Aeson LVAD	Petrus Jansen	5
	Evaheart	TBC	
	Impella 5.5 and BTR	Roberta Bogaev	5
	VADovations	James Long	
	CardioDyme	Daniel Burkhoff	
	<i>Discussion</i>		...
15:00-15:30	Coffee break		30
15:30-16:50	Acute mechanical circulatory support		80
	Moderators: Navin Kapur, Daniel Burkhoff		
	Panelists: Ralph D'Ambrosio, ..., ..., ...		
	Q&A moderator: ...		

	Acute MCS state of the art	Jakob Moeller	7
	ECP EFS	Amir Kaki	5
	TandemHeart	TBC	
	Aortix EFS	Jace Heuring	5
	SecondHeart	Leslie Miller	5
	Puzzle	TBC	
	PreCardia EFS	Navin Kapur	5
	PreCardia clinical case	Michael Kiernan	5
	New Impella RP	Christoph Nix	5
	IABP	TBC	5
	Insights from the PULSE Trial & iVAC 2L in MCS facilitated high-risk PCI	Nicolas Van Mieghem	5
	<i>Discussion</i>		...
16:50 – 18:00	New and upcoming concepts and devices		70
	Moderators: Navin Kapur, Daniel Burkhoff		
	Panelists:,,, Eberhard Grube		
	Q&A moderator:		
	Synchronized diaphragmatic stimulation for the treatment of symptomatic heart failure	Lee Goldberg	5
	Importance of mitral valve plane movement in heart pumping - updated insights	Ellen Ostenfeld	5
	Syntach - a novel minimally invasive cardiac support system	Kristian Solem	5
	Doraya	Ulrich Jorde	5
	Cardiac Booster	Florian Ludwig	5

	Targeting enhanced decongestion while aiming to preserve renal function – lymphatic-powered interstitial decongestion	Sitaramesh Emani	5
	Percutaneous pericardial resection	Barry Borlaug	5
	Sequana	Jeff Testani	
	<i>Discussion</i>		30
18:00-19:00	DDW		120
	Moderators:,		
	Panelists:,,,		
	Q&A moderator:		
 or
 or
 or
 or
 or
 or
 or
	<i>Discussion</i>		...
Saturday, December 11			
Time	Title	Speaker	Min
07:00 – 08:00	Breakfast and e-posters		60
8:00-8:40	Electrotherapy for heart failure treatment		40
	Moderators:, Randy Lee, Kalyanam Shivkumar		
	Panelists:,,,		

	Q&A moderator:		
	Cardiac contractility modulation	TBC	7
	CCM – Closing the gap: When OMT is not enough	Hendrik Bonnemeier	7
	HIS Bundle stimulation	TBC	7
	New results from the landmark REVERSE trial: More patients may benefit from CRT therapy!	TBC	7
	<i>Discussion</i>		...
8:40-10:30	Interatrial shunts		110
	Moderators: William Abraham, Daniel Burkhoff		
	Panelists: <i>Sanjiv Shah</i> , Dietmar Schranz, Martin Bergmann, Lars Lund		
	The physiological rationale for IASD as a treatment for heart failure	Daniel Burkhoff	10
	Lessons learned and being learned from the Corvia Reduce LAP-2 Study	<i>Sanjiv Shah</i>	7
	IASD across the spectrum of EFs	Josep Rodés-Cabau	7
	Are different size shunts required?	Martin W. Bergmann	7
	Is a device implant necessary for effective interatrial shunt?	Lars Lund	7
	Alternate means of creating a durable shunt without leaving a device behind: Noya	Chaim Lotan	7
	Alternate means of creating a durable shunt without leaving a device behind: InterShunt	Horst Sievert	7
	Interatrial shunting for pulmonary hypertension	William Abraham	7
	Clinical trial considerations for IASD pivotal studies	Gregg Stone	7
	Interatrial shunt for end-stage amyloid heart disease (recorded case)	Horst Sievert	7

	<i>Discussion</i>		27
10:30-11:00	Coffee break		30
11:00-13:00	Valve interventions in patients with heart failure		120
	Moderators: Nicolas Van Mieghem, Hüseyin Ince, Eberhard Grube		
	Panelists: Issam Moussa,,,		
	Q&A moderator:		
	Introduction	Hüseyin Ince	2
	Recent innovations for the management of patients with valvular heart disease – focus on heart failure	<i>Catherine M. Otto</i>	7
	<i>Discussion</i>		4
	2021 European guidelines on heart failure – focus on heart valves	Marco Metra	7
	<i>Discussion</i>		4
	Echo criteria to identify TEER responders beyond COAPT	Martin Swaans	7
	<i>Discussion</i>		4
	Volume outcome relation in percutaneous FMR treatment	Alper Öner	7
	<i>Discussion</i>		4
	Role of the right sided heart in FMR	<i>Jeroen Bax</i>	7
	<i>Discussion</i>		4
	The impact of tricuspid regurgitation on patient outcomes	David Messika-Zeitoun	7
	<i>Discussion</i>		4
	What do the guidelines say about tricuspid regurgitation?	Marco Metra	7
	<i>Discussion</i>		4
	Status on transcatheter tricuspid valve interventions – when & how	Philip Raake	7
	<i>Discussion</i>		4
	The current evidence and the vast clinical study & registry pipeline	Joerg Hausleiter	7

	<i>Discussion</i>		4
	Case presentation: improving patient outcomes and QoL with a new device (PASCAL Ace)	Wolfgang Rottbauer	7
	<i>Discussion</i>		4
	Prevalence, prognosis, and management of exercise-induced severe MR in patients with heart failure	Issam Moussa	7
	<i>Discussion</i>		4
	Closing remarks	Nicolas Van Mieghem	2
13:00-13:15	Pick up your lunch box		15
13:15-14:15	Interventions for LV reconstruction and support		60
	Moderators: Horst Sievert, Daniel Burkhoff		
	Panelists: Martin Swaans, Ralph Stephan von Bardeleben,,		
	Q&A moderator:		
	Therapeutic opportunity & single center experience	Patrick Klein	7
	Predictors of Revivent LV restoration outcomes	Rishi Puri	7
	The AccuCinch Ventricular Restoration System	Ulrich Jorde	7
	V-sling: A left ventricular transcatheter repair device for HFrEF	Horst Sievert	7
	Transcatheter intramyocardial hydrogel injection (XDrop): FIM results	Ling Tao	7
	Percutaneous radiofrequency ablation of HOCM	Liwen Liu	7
	<i>Discussion</i>		...
14:15-15:30	Right heart failure		75
	Moderators: Ralph Stephan von Bardeleben, Gry Dahle		

	Panelists: Markus Ferrari, Daniel Burkhoff		
	Q&A moderator: Daniel Kretzschmar		
	Pathology and pathophysiology, clinical relevance of RHF-does it help to treat TR?	Gry Dahle	7
	<i>Discussion</i>		5
	Evaluation of right ventricular function and its importance in RHF	Martin Swaans	7
	<i>Discussion</i>		5
	Right heart failure in the guidelines	Gry Dahle	7
	Discussion		5
	Mechanical assist in RHF using Impella RP	TBC	7
	<i>Discussion</i>		5
	Mechanical assist in RHF using the PERKAT RV pulsatile right ventricular support device	Markus Ferrari	7
	<i>Discussion</i>		5
	PHT in RHF, monitoring and treatment	Ralph Stephan von Bardeleben	7
	<i>Discussion</i>		5
	Tricuspid trial for RHF: Haemodynamic perspective	Daniel Burkhoff	7
	<i>Discussion</i>		8
15:30-16:00	Coffee break		30
16:00-17:20	The future of device-based therapies and diagnostics for heart failure		80
	Moderator: Howard Levin		
	Q&A moderator:		
	Panelists: Philip Adamson, William Abraham, Robin Germany, Todd Brinton, Kenneth Stein		

	CMO view		
	<i>Panel discussion</i>		45
	Cardiovascular innovations in Corona time	<i>Yuval Binur</i>	8
	We now have a drug therapy which is effective in HFpEF: Do we still need a device based therapy	Deepak L. Bhatt	8
	<i>Panel discussion</i>		19
17:10-18:00	I am confused! Out of these 50+ treatment options – when to use what?		50
	Moderators: Stefan Anker, Eberhard Grube , Kalyanam Shivkumar ,		
	Panelists:,,,		
	Q&A moderator:		
	Case 1	<i>Kolja Sievert</i>	7
	<i>Discussion</i>		3
	Case 2	Kerstin Piayda	7
	<i>Discussion</i>		3
	Case 3	<i>Judith Steffan</i>	7
	<i>Discussion</i>		3
	Case 4	Natalia Galeru	7
	<i>Discussion</i>		3